http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2646590-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc47bc489ff1060da96a3799235e4543 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20071 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2013-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f0b450cc064943f7839c2797c6df373 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cc17638002802ab6dd9b0c4ad9d222b |
| publicationDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2646590-T3 |
| titleOfInvention | Polynucleotides for the treatment of tumors positive for oncogenic viral polypeptides |
| abstract | An isolated polynucleotide comprising: a first nucleotide sequence encoding a first antigenic polypeptide, wherein the first antigenic polypeptide: a. comprises an amino acid sequence that has at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 29; b. is capable of initiating an immune response against the first oncogenic viral polypeptide in an immunocompetent host; and c. it is not oncogenic in the immunocompetent host; and a second nucleotide sequence encoding a second antigenic polypeptide, wherein the second antigenic polypeptide: a. comprises an amino acid sequence that has at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 30; b. is capable of initiating an immune response against the second oncogenic viral polypeptide in an immunocompetent host; and c. it is not oncogenic in the immunocompetent host; wherein the first antigenic polypeptide has the following mutations with respect to SEQ ID NO: 2: a. a point mutation or deletion in L50; b. a point mutation or deletion in E148; C. a point mutation or deletion in T149; d. a point mutation or deletion in Q150; and e. a point mutation or deletion in L151; and wherein the second antigenic polypeptide has the following mutations with respect to SEQ ID NO: 4: a. a point mutation or deletion in H2; b. a point mutation or deletion in C24; C. a point mutation or deletion in E46; and d. a point mutation or deletion in L67. |
| priorityDate | 2012-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 348.